The anti-HER2 ADC GQ1005 has shown some positive preliminary data in a phase Ia/Ib study, recruiting patients with HER2 expression (IHC2+/3+) GC (26 patients) among other HER2 cancer types (breast and lung). The gene discussed is ERBB2; the disease is cancer.